CHPPC联合静脉化疗对老年胃癌患者肿瘤标志物含量及免疫功能的影响-东南大学学报医学版

CHPPC联合静脉化疗对老年胃癌患者肿瘤标志物含量及免疫功能的影响

单位：1. 南通大学附属医院胃肠外科, 江苏南通 226000;
2. 南通大学附属医院肿瘤化疗科, 江苏南通 226000

分类号：R735.2;R730.53

出版年·卷·期（页码）：2017·36·第三期（439-443）

摘要：

目的：探讨循环腹腔热灌注化疗（CHPPC）联合静脉化疗对老年胃癌患者术后肿瘤标志物含量及机体免疫功能的影响。方法：将104例胃癌患者按数字表法随机纳入对照组（行单纯静脉化疗）和研究组（行CHPPC联合静脉化疗）各52例，比较两组患者短期化疗效果、肿瘤标志物表达量、免疫功能、药物毒副作用、复发率及生存率的差异。结果：研究组与对照组短期治疗有效率（67.3%vs 28.8%）及肿瘤标志物CEA （3.42±2.44 vs 9.64±4.53）、CA199（15.44±4.35 vs 29.52±9.53）、CA242（4.31±2.52 vs 18.7±7.45）差异均具有统计学意义（P<0.05）；且两组CD3⁺、CD4⁺、CD8⁺及CD4⁺/CD8⁺值差异也有统计学意义（P<0.05）；此外研究组复发率（19.2%）低于对照组（48.0%）（P<0.05）。结论：采用CHPPC联合静脉化疗治疗老年胃癌患者，有助于提高患者短期治疗效果，并降低患者肿瘤标志物表达水平，提高免疫功能。

Objective:To evaluate the clinical effect of continuous hyperthermic peritoneal perfusion chemotherapy(CHPPC)combined with intravenous chemotherapy on tumor marker contents and immune function in elderly patients with gastric cancer. Methods:One hundred and four patients with gastric cancer were randomly divided into control group with intravenous chemotherapy only(n=52)and study group with CHPPC combined with intravenous chemotherapy(n=52)according to the digital table. The difference of short-term chemotherapeutic effect, tumor marker expression levels, immune function, medication side effects, recurrence and survival rate were compared between the two groups. Results:There was a statistically significant difference between the two groups in short-term therapeutic response rate(67.3% vs 28.8%), tumor markers CEA(3.42±2.44 vs 9.64±4.53), CA199(15.44±4.35 vs 29.52±9.53)and CA242(4.31±2.52 vs 18.7±7.45)(P<0.05).In addition, statistically significant differences were found in the levels of CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ between the two groups(P<0.05). The recurrence rate in the study group(19.2%)was significantly lower than that in the control group(48.0%)(P<0.05). Conclusion:CHPPC combined with intravenous chemotherapy in the treatment of elderly patients with gastric cancer can improve the short-term therapeutic effect and immune function, and reduce the expression levels of tumor markers.

参考文献：

[1] GUGGENHEIM D E,SHAN M A.Gastric cancer epidemiology and risk factors[J].J Surg Oncol,2013,107(3):230-236.
[2] 王欢,向明飞,刘罡,等.94853例恶性肿瘤住院患者疾病构成及死因分析[J].东南大学学报:医学版,2014(2):187-191.
[3] 李旭哲,刘斌正,马雅静,等.胃癌患者术前血液中钾、钠、氯、镁、磷的相关性及其对生存预后的影响[J].中国现代医学杂志,2016,26(11):34-39
[4] 王俞,崔书中,巴明臣.腹腔热灌注化疗联合免疫治疗在恶性腹水中的应用[J].临床肿瘤学杂志,2013,18(11):1041-1044.
[5] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[6] 李家泰.临床药理[M].北京:人民卫生出版社,1996:594.
[7] 朱捷,丁皓,王校红.胃癌腹膜转移相关基因MYH-9与胃癌转移及其预后的关系[J].实用癌症杂志,2016,31(2):195-197.
[8] KODERA Y,FUJITANI K,FUKUSHIMA N,et al.Surgical resection of hepatic metastasis from gastric cancer:a review and new recommendation in the Japanese gastric cancer treatment guidelines[J].Gastric Cancer,2014,17(2):206-212.
[9] 吴晓江,贾永宁,季加孚.腹腔热灌注化疗在胃癌腹腔转移治疗中的价值[J].中国实用外科杂志,2015,35(10):1071-1075.
[10] 陈小辉,李雅丽.腹腔热灌注联合新辅助化疗在提高晚期上皮性卵巢癌二次减灭术有效率中的作用[J].中华实用诊断与治疗杂志,2015,29(9):929-931.
[11] ELIAS D,GOERE D,DUMONT F,et al.Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases[J].Eur J Cancer,2014,50(2):332-340.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录